1. Home
  2. Analysis
  3. Ramipril
  4. Zejula

Ramipril and Zejula drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ramipril (ramipril) and Zejula (niraparib tosylate). Common drug interactions include constipation among females.

The phase IV clinical study analyzes what interactions people have when they take Ramipril and Zejula. It is created by eHealthMe based on reports of 41 people who take the same drugs from the FDA, and is updated regularly.

What is Ramipril?

Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 147,397 Ramipril users. Check the latest studies of Ramipril.

What is Zejula?

Zejula has active ingredients of niraparib tosylate. eHealthMe is studying from 22,014 Zejula users. Check the latest studies of Zejula.

On Jul, 14, 2026

41 people who take Ramipril and Zejula together, and have interactions are studied.

Ramipril and Zejula drug interactions.

What are the common drug interactions of Ramipril and Zejula, by gender? *:

female:

  1. Constipation
  2. Nausea (feeling of having an urge to vomit)
  3. Anxiety
  4. Productive cough
  5. Retching (strong involuntary effort to vomit)
  6. Hepatic enzyme increased
  7. Corneal deposits
  8. Malignant neoplasm progression (cancer tumour came back)
  9. Dyspnoea (difficult or laboured respiration)
  10. Carbohydrate antigen 125 increased

male:

n/a

What are the common drug interactions of Ramipril and Zejula, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Anxiety
  2. Constipation
  3. Decreased appetite
  4. Haemoglobin decreased
  5. Nausea (feeling of having an urge to vomit)
  6. Platelet count decreased
  7. Productive cough
  8. Red blood cell count decreased
  9. Retching (strong involuntary effort to vomit)
  10. Vomiting

60+:

  1. Fatigue (feeling of tiredness)
  2. Abdominal hernia
  3. Dysgraphia (impaired ability to learn to write)
  4. Early satiety (feeling full before completing a normal sized meal)
  5. Globulins increased
  6. Hot flush (sudden feelings of heat)
  7. Hypoaesthesia (reduced sense of touch or sensation)
  8. Lymphadenopathy (disease or enlargement of lymph nodes)
  9. Muscle spasms (muscle contraction)
  10. Myalgia (muscle pain)

What are the existing conditions these people have? *

  1. Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 24 people, 58.54%
  2. Fallopian Tube Cancer (cancer of fallopian tube): 23 people, 56.10%
  3. Ovarian Epithelial Cancer (cancer that begins in the cells on the surface of the ovary): 16 people, 39.02%
  4. Ovarian Cancer (cancer of ovary): 15 people, 36.59%
  5. Ovarian Epithelial Cancer Recurrent (reoccurrence of cancer that begins in the cells on the surface of the ovary): 6 people, 14.63%

* Approximation only. Some reports may have incomplete information.

Do you take Ramipril and Zejula?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ramipril and Zejula:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ramipril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zejula:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ramipril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zejula and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ramipril and niraparib tosylate (the active ingredients of Ramipril and Zejula, respectively), and Ramipril and Zejula (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.